Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

    • insulins

    - PMLiVE

    Merck ends development agreement with Dr Falk Pharma for monoclonal antibody

    Merck will take full control of developing MK-8690, an investigational monoclonal antibody candidate

    EU flag

    EC approves Biocon Biologics’ denosumab biosimilars Vevzuo and Evfraxy

    An estimated 32 million people aged 50 years and over in Europe were living with osteoporosis in 2019

    - PMLiVE

    FDA grants interchangeable designation to Celltrion’s Humira biosimilar Yuflyma

    The drug is approved for inflammatory conditions such as Crohn's disease and plaque psoriasis

    EU flag

    EC approves Biocon’s Stelara biosimilar Yesintek for inflammatory diseases

    The drug has been approved to treat plaque psoriasis, psoriatic arthritis and Crohn’s disease

    - PMLiVE

    Chiesi Group invests €400m to establish biotech centre of excellence in Italy

    The facility is dedicated to developing and producing monoclonal antibodies, enzymes and other proteins

    EU flag

    EC approves Celltrion’s Stelara biosimilar SteQeyma for inflammatory diseases

    The drug has been authorised for use in gastroenterology, dermatology and rheumatology indications

    - PMLiVE

    Sandoz separates from Novartis as an independent spin-off company

    The split allows Sandoz to strengthen its position in generics and biosimilars

    - PMLiVE

    Sandoz launches high-concentration biosimilar of AbbVie’s Humira in the US

    Hyrimoz HCF is approved to treat indications including rheumatoid arthritis and Crohn’s disease

    - PMLiVE

    Sandoz and Just-Evotec Biologics announce multi-year biosimilar partnership

    The Novartis unit will aim to expand its current pipeline of biosimilars to about 24 candidates

    - PMLiVE

    Sandoz launches ‘Act4Biosimilars’ initiative to address global health inequalities

    The initiative wants to increase the global use of biosimilars by at least 30% by 2030

    - PMLiVE

    Sandoz launches generic oncology treatment in Europe

    Lenalidomide can be used to treat patients with haemato-onocology conditions, following recommendations from recent European Society for Medical Oncology (ESMO) guidelines

    - PMLiVE

    Biosimilars boosted by FDA’s landmark ruling for Boehringer’s Cyltezo

    The FDA has approved Boehringer’s Cyltezo (adalimumab-adbm) as ‘interchangeable’ with Humira (adalimumab) in a landmark ruling

    Subscribe to our email news alerts

    Latest content

    Latest intelligence

    Quick links